Ernexa Therapeutics Inc. Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent
Ernexa Therapeutics Inc. (ERNA) reported Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent of -$23.00 thousand for the 12-month period ending 2020-12-31, per its 10-K filed 2021-03-11.
Discontinued › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentBeforeTaxPortionAttributableToParent · last filed 2021-03-11
- Ernexa Therapeutics Inc. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, portion attributable to parent for the quarter ending 2020-12-31 was $4.00K, a 80.95% decline year-over-year.
- Ernexa Therapeutics Inc. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, portion attributable to parent for the quarter ending 2020-09-30 was $1.00K.
- Ernexa Therapeutics Inc. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, portion attributable to parent for the quarter ending 2020-06-30 was $76.00K, a 137.50% increase year-over-year.
- Ernexa Therapeutics Inc. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, portion attributable to parent for the quarter ending 2020-03-31 was -$104.00K, a 415.15% decline year-over-year.
- Ernexa Therapeutics Inc. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, portion attributable to parent for fiscal 2020 was -$23.00K, a 133.82% decline from fiscal 2019.
- Ernexa Therapeutics Inc. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, portion attributable to parent for fiscal 2019 was $68.00K.
- Ernexa Therapeutics Inc. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, portion attributable to parent for fiscal 2018 was -$145.00K, a 218.85% decline from fiscal 2017.
- Ernexa Therapeutics Inc. other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, portion attributable to parent for fiscal 2017 was $122.00K, a 139.22% increase from fiscal 2016.
| Period end | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent 3 month | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent 6 month | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent 9 month | Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax, Portion Attributable to Parent 12 month |
|---|---|---|---|---|
| 2020-12-31 | $4.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $5.00K derived: sum of 2 quarters · filed 2021-03-11 | $81.00K derived: sum of 3 quarters · filed 2021-03-11 | -$23.00K 10-K · filed 2021-03-11 |
| 2020-09-30 | $1.00K 10-Q · filed 2020-11-13 | $77.00K derived: sum of 2 quarters · filed 2020-11-13 | -$27.00K 10-Q · filed 2020-11-13 | -$6.00K derived: sum of 4 quarters · filed 2021-03-11 |
| 2020-06-30 | $76.00K 10-Q · filed 2020-08-07 | -$28.00K 10-Q · filed 2020-08-07 | -$7.00K derived: sum of 3 quarters · filed 2021-03-11 | -$25.00K derived: sum of 4 quarters · filed 2021-03-11 |
| 2020-03-31 | -$104.00K 10-Q · filed 2020-05-20 | -$83.00K derived: sum of 2 quarters · filed 2021-03-11 | -$101.00K derived: sum of 3 quarters · filed 2021-03-11 | -$69.00K derived: sum of 4 quarters · filed 2021-03-11 |
| 2019-12-31 | $21.00K derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11 | $3.00K derived: sum of 2 quarters · filed 2021-03-11 | $35.00K derived: sum of 3 quarters · filed 2021-03-11 | $68.00K 10-K · filed 2021-03-11 |
| 2019-09-30 | -$18.00K 10-Q · filed 2020-11-13 | $14.00K derived: sum of 2 quarters · filed 2020-11-13 | $47.00K 10-Q · filed 2020-11-13 | -$46.00K derived: sum of 4 quarters · filed 2020-11-13 |
| 2019-06-30 | $32.00K 10-Q · filed 2020-08-07 | $65.00K 10-Q · filed 2020-08-07 | -$28.00K derived: sum of 3 quarters · filed 2020-08-07 | $11.00K derived: sum of 4 quarters · filed 2020-08-07 |
| 2019-03-31 | $33.00K 10-Q · filed 2020-05-20 | -$60.00K derived: sum of 2 quarters · filed 2020-05-20 | -$21.00K derived: sum of 3 quarters · filed 2020-05-20 | -$64.00K derived: sum of 4 quarters · filed 2020-05-20 |
| 2018-12-31 | -$93.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-19 | -$54.00K derived: sum of 2 quarters · filed 2020-03-19 | -$97.00K derived: sum of 3 quarters · filed 2020-03-19 | -$145.00K 10-K · filed 2020-03-19 |
| 2018-09-30 | $39.00K 10-Q · filed 2019-11-01 | -$4.00K derived: sum of 2 quarters · filed 2019-11-01 | -$52.00K 10-Q · filed 2019-11-01 | -$66.00K derived: sum of 4 quarters · filed 2019-11-01 |
| 2018-06-30 | -$43.00K 10-Q · filed 2019-08-12 | -$91.00K 10-Q · filed 2019-08-12 | -$105.00K derived: sum of 3 quarters · filed 2019-08-12 | -$25.00K derived: sum of 4 quarters · filed 2019-08-12 |
| 2018-03-31 | -$48.00K 10-Q · filed 2019-05-14 | -$62.00K derived: sum of 2 quarters · filed 2019-05-14 | $18.00K derived: sum of 3 quarters · filed 2019-05-14 | $59.00K derived: sum of 4 quarters · filed 2019-05-14 |
| 2017-12-31 | -$14.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-22 | $66.00K derived: sum of 2 quarters · filed 2019-03-22 | $107.00K derived: sum of 3 quarters · filed 2019-03-22 | $122.00K 10-K · filed 2019-03-22 |
| 2017-09-30 | $80.00K 10-Q · filed 2018-11-09 | $121.00K derived: sum of 2 quarters · filed 2018-11-09 | $136.00K 10-Q · filed 2018-11-09 | $97.00K derived: sum of 4 quarters · filed 2018-11-09 |
| 2017-06-30 | $41.00K 10-Q · filed 2018-08-06 | $56.00K 10-Q · filed 2018-08-06 | $17.00K derived: sum of 3 quarters · filed 2018-08-06 | -$8.00K derived: sum of 4 quarters · filed 2018-08-06 |
| 2017-03-31 | $15.00K 10-Q · filed 2018-05-11 | -$24.00K derived: sum of 2 quarters · filed 2018-05-11 | -$49.00K derived: sum of 3 quarters · filed 2018-05-11 | -$47.00K derived: sum of 4 quarters · filed 2018-05-11 |
| 2016-12-31 | -$39.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-09 | -$64.00K derived: sum of 2 quarters · filed 2018-03-09 | -$62.00K derived: sum of 3 quarters · filed 2018-03-09 | $51.00K 10-K · filed 2018-03-09 |
| 2016-09-30 | -$25.00K 10-Q · filed 2017-11-08 | -$23.00K derived: sum of 2 quarters · filed 2017-11-08 | $90.00K 10-Q · filed 2017-11-08 | $34.00K derived: sum of 4 quarters · filed 2017-11-08 |
| 2016-06-30 | $2.00K 10-Q · filed 2017-08-04 | $115.00K 10-Q · filed 2017-08-04 | $59.00K derived: sum of 3 quarters · filed 2017-08-04 | -$81.00K derived: sum of 4 quarters · filed 2017-08-04 |
| 2016-03-31 | $113.00K 10-Q · filed 2017-05-04 | $57.00K derived: sum of 2 quarters · filed 2017-05-04 | -$83.00K derived: sum of 3 quarters · filed 2017-05-04 | -$41.00K derived: sum of 4 quarters · filed 2017-05-04 |
| 2015-12-31 | -$56.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-09 | -$196.00K derived: sum of 2 quarters · filed 2017-03-09 | -$154.00K derived: sum of 3 quarters · filed 2017-03-09 | -$307.00K 10-K · filed 2017-03-09 |
| 2015-09-30 | -$140.00K 10-Q · filed 2016-11-09 | -$98.00K derived: sum of 2 quarters · filed 2016-11-09 | -$251.00K 10-Q · filed 2016-11-09 | -$325.00K derived: sum of 4 quarters · filed 2016-11-09 |
| 2015-06-30 | $42.00K 10-Q · filed 2016-08-04 | -$111.00K 10-Q · filed 2016-08-04 | -$185.00K derived: sum of 3 quarters · filed 2016-08-04 | -$267.00K derived: sum of 4 quarters · filed 2016-08-04 |
| 2015-03-31 | -$153.00K 10-Q · filed 2016-05-09 | -$227.00K derived: sum of 2 quarters · filed 2016-05-09 | -$309.00K derived: sum of 3 quarters · filed 2016-05-09 | -$242.00K derived: sum of 4 quarters · filed 2016-05-09 |
| 2014-12-31 | -$74.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | -$156.00K derived: sum of 2 quarters · filed 2016-03-15 | -$89.00K derived: sum of 3 quarters · filed 2016-03-15 | -$152.00K 10-K · filed 2016-03-15 |
| 2014-09-30 | -$82.00K 10-Q · filed 2015-11-09 | -$15.00K derived: sum of 2 quarters · filed 2015-11-09 | -$78.00K 10-Q · filed 2015-11-09 | -$148.00K derived: sum of 4 quarters · filed 2015-11-09 |
| 2014-06-30 | $67.00K 10-Q · filed 2015-08-10 | $4.00K 10-Q · filed 2015-08-10 | -$66.00K derived: sum of 3 quarters · filed 2015-08-10 | -$26.00K derived: sum of 4 quarters · filed 2015-08-10 |
| 2014-03-31 | -$63.00K 10-Q · filed 2015-05-08 | -$133.00K derived: sum of 2 quarters · filed 2015-05-08 | -$93.00K derived: sum of 3 quarters · filed 2015-05-08 | -$158.00K derived: sum of 4 quarters · filed 2015-05-08 |
| 2013-12-31 | -$70.00K derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-31 | -$30.00K derived: sum of 2 quarters · filed 2014-11-07 | -$95.00K derived: sum of 3 quarters · filed 2014-11-07 | -$137.00K 10-K · filed 2014-03-31 |
| 2013-09-30 | $40.00K 10-Q · filed 2014-11-07 | -$25.00K derived: sum of 2 quarters · filed 2014-11-07 | -$67.00K 10-Q · filed 2014-11-07 | |
| 2013-06-30 | -$65.00K 10-Q · filed 2014-08-14 | -$107.00K 10-Q · filed 2014-08-14 | ||
| 2013-03-31 | -$42.00K 10-Q · filed 2014-05-15 | |||
| 2012-12-31 | $46.00K 10-K · filed 2014-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |
| SYNLOGIC, INC. (SYBX) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B |